{
    "clinical_study": {
        "@rank": "168310", 
        "arm_group": {
            "arm_group_label": "All Enrolled Participants", 
            "arm_group_type": "Experimental", 
            "description": "Each participant receives all treatments (of placebo, dronabinol 10 mg and dronabinol 30 mg) in a 5-way crossover design. At each treatment visit, participants receive a single dose, contained in two syringes of oral solution and three capsules.  When dronabinol is in syringes, placebo is in capsules, and when dronabinol is in capsules, placebo is in syringes.  When assigned to take placebo only, placebo is in both the syringes and the capsules."
        }, 
        "brief_summary": {
            "textblock": "The primary objective of this study is to evaluate the abuse potential of dronabinol oral\n      solution in recreational cannabinoid users."
        }, 
        "brief_title": "A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "condition": "Drug Abuse, Medication", 
        "condition_browse": {
            "mesh_term": "Substance-Related Disorders"
        }, 
        "detailed_description": {
            "textblock": "Following a four-day period for screening and qualification, there are five treatment visits\n      with a minimum 8-day washout between treatments.  Each participant will receive all\n      treatments in a 5-way crossover design."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy adult protocol-defined recreational cannabinoid user\n\n          -  Meets protocol-specified criteria for qualification and contraception\n\n          -  Able to speak, read and understand English well enough to understand the nature of\n             the study, provide written informed consent, and to allow completion of all study\n             assessments\n\n          -  Provides written informed consent prior to any protocol-specific procedures, and\n             agrees to abide by all protocol-specified requirements and restrictions\n\n        Exclusion Criteria:\n\n          -  Dependence on any substance other than nicotine or caffeine beyond protocol-specified\n             limits\n\n          -  Signs, symptoms or history of any condition that, per protocol or in the opinion of\n             the investigator, might compromise: 1) the safety or well-being of the participant or\n             study staff,  2) the safety or well-being of the participant's offspring (such as\n             through pregnancy or breast-feeding), 3) the analysis of results\n\n          -  Unwilling, unable, or unlikely to follow protocol-specified restrictions on food,\n             drink, nicotine or physical activities (such as exercise and driving)\n\n          -  An employee of the sponsor or research site personnel directly affiliated with this\n             study or their immediate biological or adopted family member defined as a spouse,\n             parent, child or sibling"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "43", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02094599", 
            "org_study_id": "INS-13-017"
        }, 
        "intervention": [
            {
                "arm_group_label": "All Enrolled Participants", 
                "description": "Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes.", 
                "intervention_name": "Dronabinol 10 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "All Enrolled Participants", 
                "description": "Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes.", 
                "intervention_name": "Dronabinol 30 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "All Enrolled Participants", 
                "description": "Matching placebo provided in capsules or as an oral solution in syringes.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Tetrahydrocannabinol"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Toronto", 
                    "country": "Canada", 
                    "state": "Ontario", 
                    "zip": "M5V 2T3"
                }, 
                "name": "INC Research Toronto, Inc."
            }
        }, 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Single-dose, Double-blind, Double-dummy, Randomized, Placebo- and Active-controlled Crossover Study to Evaluate the Abuse Potential of Dronabinol Oral Solution in Recreational Cannabinoid Users", 
        "overall_official": [
            {
                "affiliation": "INSYS Therapeutics Inc", 
                "last_name": "Larry Dillaha, MD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "INC Research Toronto, Inc.", 
                "last_name": "Michael McDonnell, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Peak score (Emax) on Drug Liking calculated from a 100-point visual analogue scale (VAS), where 0=strong disliking and 100=strong liking", 
            "safety_issue": "No", 
            "time_frame": "within 24 hours post-dose"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02094599"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Categorical measures = Good drug effects, High, Stoned, Bad effects, Any effects", 
                "measure": "Peak score (Emax) for Drug Effects, calculated from scores on a VAS scale of 0-100, where 0=not at all and 100=extremely", 
                "safety_issue": "No", 
                "time_frame": "within 24 hours post-dose"
            }, 
            {
                "description": "Categorical measures = Euphoria, Dysphoria, Sedation, Marijuana", 
                "measure": "Peak score (Emax) for a shortened Addiction Research Center Inventory (ARCI) scale of 0-49, where 49 is the highest possible score", 
                "safety_issue": "No", 
                "time_frame": "within 24 hours post-dose"
            }, 
            {
                "measure": "Peak score (Emax) for Subjective Drug Value (SDV) in dollars", 
                "safety_issue": "No", 
                "time_frame": "within 24 hours post-dose"
            }, 
            {
                "description": "Categorical measures = Good drug effects, High, Stoned, Bad effects, Any effects", 
                "measure": "Time-averaged Area under the Effect Curve (TA_AUC) for Drug Effects, calculated from scores on a VAS scale of 0-100, where 0=not at all and 100=extremely", 
                "safety_issue": "No", 
                "time_frame": "within 24 hours post-dose"
            }, 
            {
                "measure": "Overall Drug Liking (Emax/Emin) calculated from a 100-point visual analogue scale (VAS), where 0=strong disliking and 100=strong liking", 
                "safety_issue": "No", 
                "time_frame": "within 24 hours post-dose"
            }, 
            {
                "measure": "Time-averaged Area under the Effect Curve (TA_AUC) for Drug Liking calculated from a 100-point visual analogue scale (VAS), where 0=strong disliking and 100=strong liking", 
                "safety_issue": "No", 
                "time_frame": "within 24 hours post-dose"
            }, 
            {
                "description": "Categorical measures = Euphoria, Dysphoria, Sedation, Marijuana", 
                "measure": "Time-averaged Area under the Effect Curve (TA_AUC) for a shortened Addiction Research Center Inventory (ARCI) scale of 0-49, where 49 is the highest possible score", 
                "safety_issue": "No", 
                "time_frame": "within 24 hours post-dose"
            }, 
            {
                "measure": "Trough Score (Emin) for Drug Liking calculated from a 100-point visual analogue scale (VAS), where 0=strong disliking and 100=strong liking", 
                "safety_issue": "No", 
                "time_frame": "within 24 hours post-dose"
            }, 
            {
                "measure": "Peak score (Emax) for Take Drug Again, calculated from scores on a VAS scale of 0-100, where 0=definitely not and 100=definitely so", 
                "safety_issue": "No", 
                "time_frame": "within 24 hours post-dose"
            }, 
            {
                "measure": "Peak score (Emax) for Alertness/Drowsiness, calculated from scores on a VAS scale of 0-100, where 0=very drowsy and 100=very alert", 
                "safety_issue": "No", 
                "time_frame": "within 24 hours post-dose"
            }, 
            {
                "measure": "Time-averaged Area under the Effect Curve (TA_AUC) for Alertness/Drowsiness, calculated from a 100-point visual analogue scale (VAS), where 0=very drowsy and 100=very alert", 
                "safety_issue": "No", 
                "time_frame": "within 24 hours post-dose"
            }
        ], 
        "source": "INSYS Therapeutics Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "INSYS Therapeutics Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}